Incyte (INCY) PT Set at $145.00 by Credit Suisse Group
Incyte (NASDAQ:INCY) has been given a $145.00 price target by investment analysts at Credit Suisse Group in a report released on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective suggests a potential upside of 64.46% from the company’s previous close.
Several other analysts have also weighed in on INCY. Nomura reissued a “buy” rating on shares of Incyte in a report on Thursday, February 1st. BidaskClub lowered Incyte from a “sell” rating to a “strong sell” rating in a report on Thursday, February 1st. Oppenheimer set a $120.00 target price on Incyte and gave the company a “hold” rating in a report on Tuesday, January 2nd. TheStreet lowered Incyte from a “c-” rating to a “d+” rating in a report on Tuesday, December 5th. Finally, Cowen reissued a “buy” rating on shares of Incyte in a report on Tuesday, December 5th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Incyte presently has an average rating of “Buy” and an average price target of $142.94.
Shares of Incyte (NASDAQ:INCY) opened at $88.17 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. The firm has a market capitalization of $18,577.61, a price-to-earnings ratio of -110.21 and a beta of 0.59. Incyte has a twelve month low of $80.85 and a twelve month high of $153.15.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Financial Gravity Companies Inc. purchased a new position in Incyte during the fourth quarter worth about $120,000. Private Advisor Group LLC purchased a new position in Incyte during the third quarter worth about $203,000. Advantage Investment Management LLC lifted its position in Incyte by 1,233.3% during the fourth quarter. Advantage Investment Management LLC now owns 2,000 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 1,850 shares during the period. Caxton Associates LP purchased a new position in Incyte during the third quarter worth about $257,000. Finally, Mission Wealth Management LP purchased a new position in Incyte during the fourth quarter worth about $213,000. Hedge funds and other institutional investors own 90.02% of the company’s stock.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.